Key facts
- This page summarizes Michael Aaron Kelly's Form 4 filing for Aprea Therapeutics, Inc. (APRE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Jul 2021, 19:07.
Michael Aaron Kelly - 30 Jun 2021 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)
- Reporting relationship
- Director
- Issuer ticker
- APRE
- Reported as of
- 30 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jul 2021, 19:07:34 UTC
- Prior SEC filing
- 14 Jun 2021
- Next SEC filing
- 12 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott M. Coiante, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Aaron Kelly filed Form 4 for Aprea Therapeutics, Inc. (APRE) on 01 Jul 2021.
Change
- Previous filing in this sequence was filed on 14 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APRE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,610
- Change %
- Price
- $0.000000
- Shares after
- 4,610
- Date
- 30 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APRE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +22,750
- Change %
- Price
- $0.000000
- Shares after
- 22,750
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,750
- Exercise price
- $4.88
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
Footnote F2
The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.